Remote ischemic conditioning improves cognition in patients with subcortical ischemic vascular dementia

• Main Authors: Zhangyuan Liao, Yali Bu, Meijie Li, Ranran Han, Nan Zhang, Junwei Hao, Wei Jiang
• Format: Article
• Language: English
• Published: BMC 2019-08-01
• Series: BMC Neurology
• Subjects: Ischemic conditioning; Cerebral small vessel disease; Subcortical ischemic vascular dementia; Cognition; White matter lesion; Diffusion tension imaging
• Online Access: http://link.springer.com/article/10.1186/s12883-019-1435-y

Abstract Background Subcortical ischemic vascular dementia (SIVD) is very common among the older people, but has no approved treatment. Preclinical trials show that remote ischemic conditioning (RIC) reduces recurrence of ischemic stroke. We hypothesize that RIC may also be an effective therapy for patients with SIVD. Methods Thirty-seven consecutive SIVD cases were enrolled in this randomized control study. Eighteen RIC patients underwent five brief cycles of conditioning (bilateral upper limb compression at 200 mmHg) followed by reperfusion twice daily over 6 consecutive months. Nineteen control patients underwent the same process, but at a pressure of 60 mmHg which caused no restriction on the blood flow of the upper limb. The primary outcome measures were changes in neuropsychological assessments. The secondary outcomes included the changes in high-sensitive C-reactive protein (hs-CRP) concentration, white matter lesion volume (WMLV), diffusion tension imaging (DTI) metrics of white matter. All data were collected at baseline and follow-up. Results A significant treatment difference favoring RIC at 6 months was observed on performance of Hopkins Verbal Learning Test-Revised (HVLT-R), Controlled Oral Word Association Test (COWAT), Trail Making Test A and B (TMT-A & TMT-B), and Judgment of Line Orientation (JLO) (p < 0.05). The control group did not show much improvement after the treatment, and only with a slight change in HVLT-R and TMT-R (p < 0.05). Covariance analysis of efficacy between the two groups suggested that RIC patients performed better on JLO than control patients at the 6-month follow-up (RIC 23.10 vs. control 18.56; p = 0.013). Although DTI metrics were comparable, Hs-CRP levels and WMLV in RIC patients showed a declining trend. Conclusions Over the 6-month treatment period, we found that RIC was safe and effective for improving cognitive function in SIVD patients. Trial registration Clinical Trial Registration (http://www.clinicaltrials.gov), Unique identifier: NCT 03022149; Retrospectively registered; Date of registration: January 16, 2017.